Cellectis Car T Cells

Clls a clinical stage biopharmaceutical company focused on developing immunotherapies based on gene edited allogeneic car t cells ucart announced that it will report its financial results for the second quarter of 2020 together with a business update on wednesday august 5 2020 after the close of the us market.

Cellectis car t cells.

Cellectis car t platform technology provides a proprietary allogeneic approach utilizing engineered t cells from a single donor for use in. Cellectis is developing a new type of chimeric antigen receptor that could improve the production and safety of car t cell therapies generated from both patient and donor cells. Cellectis is developing off the shelf car t cell treatments meant to work for any person who has certain types of blood cancer. Cellectis approach with ucart19 was based on the preliminary positive results from clinical trials using autologous car t cells but bringing the potential to overcome the limitation of the current autologous approach by providing an allogeneic frozen off the shelf t cell based medicinal product.

Before joining the cellectis trial the patient underwent multiple prior lines of treatment including with autologous car t cells without success. Cellectis said that a patient in the trial who had received numerous prior lines of therapy including autologous car t cells experienced cardiac arrest and died. The company said the death is. Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene edited engineered car t cells ucart.

About cellectis cellectis is developing the first of its kind allogeneic approach for car t immunotherapies in oncology pioneering the concept of off the shelf and ready to use gene edited car t. The company s mission is. 10 most car t therapies under development as of 2017 involved taking t cells from the person with cancer and applying gene therapy to those cells to activate them to attack the person s cancer. Cellectis a french biotech focused on developing car t therapies from donor cells has published a study in the journal scientific reports describing technological advances that could improve the safety of car t cell.

July 29 2020 new york cellectis euronext growth.